With the objective of expanding its R&D efforts in pain and neurodegeneration, US pharma major Eli Lilly (NYSE: LLY) today announced that it acquiring privately-held US biotech Disarm Therapeutics, which is creating a new class of disease-modifying therapeutics for patients with axonal degeneration.
Disarm has discovered novel, potent SARM1 inhibitors and is advancing them in pre-clinical development, with the goal of delivering breakthrough treatments to patients with peripheral neuropathy and other neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze